Remove Chemotherapy Remove Labelling Remove Patient Care
article thumbnail

STAT+: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear

STAT

The Food and Drug Administration issued a change to the warning label for Legend Biotech and Janssen’s myeloma CAR-T, Carvykti or cilta-cel, adding that some secondary blood cancers have occurred following treatment for multiple myeloma with the cell therapy. 

Labelling 112
article thumbnail

Enhancing collaboration to optimise medication therapy in older adults with cancer: a position paper from SOFOG-SFPO

Hospital Pharmacy Europe

In this heterogeneous patient group, decisions on therapies and management must follow a multidimensional approach, integrating medical, socio-economic and psychological factors. Drug classes known to cause falls are commonly used in older patients , but cancer treatment can further increase this risk.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

Kalis, PharmD, BCOP Key Takeaways Oncology pharmacy's complexity outpaces the generalist model, necessitating specialization for effective patient care and operational efficiency. Image credit: NDABCREATIVITY | stock.adobe.com And the complexity is not limited to clinical care. Carlstrom, PharmD, BCOP , Joseph A.

article thumbnail

New data reinforce Keytruda’s dominance in first-line lung cancer

pharmaphorum

Furthermore, the duration of response with the PD-1 checkpoint inhibitor was nearly five times longer at 29 months versus just over six months with frontline chemotherapy.